JPRN-UMIN000006874RecruitingPhase 2
A phase II study of Conbination therapy of Cisplatin/Pemetrexed/Bavacizumab in previously untreated patients with StageIIIB/IV or recurrent disease nonsquamous non-small cell lung cancer - A phase II study of Conbination therapy of Cisplatin/Pemetrexed/Bavacizumab in previously untreated patients with StageIIIB/IV or recurrent disease nonsquamous non-small cell lung cancer
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Sponsor
- Fukushima medical University
- Enrollment
- 37
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1)Patients with untreated Brain metastases 2)Patients with current or previous history of hemoptysis (2.5mL or more) 3)Patients with uncontrolled hyper tension 4)Patients with uncontrolled infection 5)Patients with active lung disease such as interstitial pneumonia, pneumoconiosis, active radiation pneumonitis, pulmonary fibrosis or drug-induced pneumonitis 6)Patients with uncontrollable complications 7)Patients with massive pleural or pericardial effusion,or ascites 8)Patients with active concomitant malignancy 9)Patients with previous histories of drug allergy 10)Patients with uncontrollable gastrointestinal ulceration 11)Patients with current or previous (within one year) history of gastrointestinal perforation 12)Patients with therapeutic anticoagulopathy (including Aspirin over 325mg/day) 13)Pregnancy or lactation 14)Inappropriate patients for this study judged by the physicians
Investigators
Similar Trials
Completed
Phase 1
Phase Ib study of combination therapy with Cisplatin, Irinotecan, and Ramucirumab for extensive-disease small-cell lung cancerExtensive disease small cell lung cancerJPRN-UMIN000032671Shizuoka Cancer Center10
Recruiting
Phase 2
Efficacy and safety of the combination of Cisplatin plus Nab-paclitaxel and Nivolumab with radiotherapy after maximal tumor resection in non-metastatic muscle
invasive Bladder Cancer. (CA209-6E8, CNN-BC trial)2024-518937-26-00Fondazione Policlinico Universitario Agostino Gemelli IRCCS24
Active, not recruiting
Not Applicable
A Phase II study evaluating the role of the combination of cisplatin and cyclophosphamide administered metronomically in patients with advanced breast cancer triple negative (Estrogen and progesterone receptors negative and c-erb B2 non overexpressed).Advanced, triple receptor negative breast cancerMedDRA version: 14.1Level: PTClassification code 10055113Term: Breast cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-020835-38-ITISTITUTO EUROPEO DI ONCOLOGIA
Completed
Not Applicable
Feasibility study of the combination of cisplatin and docetaxel with concurrent thoracic radiotherapy for locally advanced resectable non-small cell lung cancer.ocally advanced resectable non-small-cell lung cancerJPRN-UMIN000008130Hamamatsu University School of Medicine3
Completed
Phase 2
A randomized phase II study of Cisplatin plus S-1 versus Cisplatin plus Pemetrexed, with thoracic radiotherapy for locally advanced non-squamous non-small cell lung cancerJPRN-UMIN000009914ational Cancer Center Hospital East100